Yue-Qiang Li Selected Research

Yue-Qiang Li Research Topics

4	Fibrosis (Cirrhosis) 01/2021 - 01/2014
3	IGA Glomerulonephritis (IGA Nephropathy) 03/2020 - 01/2015
1	Hypercholesterolemia 01/2022
1	Proteinuria 01/2022
1	Membranous Glomerulonephritis (Membranous Nephropathy) 01/2022
1	Microvascular Rarefaction 01/2021
1	Myocardial Infarction 01/2021
1	Atrophy 03/2020
1	Inflammation (Inflammations) 01/2019
1	Focal Segmental Glomerulosclerosis (Glomerulosclerosis, Focal) 01/2015
1	Reperfusion Injury 08/2014
1	Chronic Renal Insufficiency 01/2014
1	Hypertension (High Blood Pressure) 01/2013

3	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2019
2	Chemotactic FactorsIBA 03/2020 - 01/2019
1	Phospholipase A2 ReceptorsIBA 01/2022
1	CholesterolIBA 01/2022
1	HDL CholesterolIBA 01/2022
1	LDL CholesterolIBA 01/2022
1	Triglycerides (Triacylglycerol)IBA 01/2022
1	oxidized low density lipoproteinIBA 01/2022
1	Leucine (L-Leucine)FDA Link 01/2021
1	CytokinesIBA 01/2021
1	Uric Acid (Urate)IBA 03/2020
1	CXC ChemokinesIBA 03/2020
1	LigandsIBA 03/2020
1	Chemokine CX3CL1IBA 01/2019
1	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 01/2015
1	Dexamethasone (Maxidex)FDA LinkGeneric 08/2014
1	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 08/2014
1	Telmisartan (Micardis)FDA Link 01/2014
1	1- (4- (2- methoxyethyl)phenoxy)- 3- (((2- 2- methoxyphenoxy)ethyl)amino)- 2- propanolIBA 01/2013
1	Carvedilol (Coreg)FDA LinkGeneric 01/2013
1	Therapeutic UsesIBA 01/2013

1	Aftercare (After-Treatment) 01/2022
1	Therapeutics 01/2013